Clinical Trial Now Enrolling

Standard treatments for pancreatic cancer are often ineffective as they cannot be directly delivered to the tumor.

A potential new option for targeted treatment is on the horizon.

Introducing RenovoCath®

Pancreatic cancer is one of the deadliest types of cancer. Despite several FDA-approved treatments, it is projected to become the second-leading cause of cancer-related death in the United States around 2020[i], in part due to challenges in diagnosing and treating the disease. It is hard to detect at an early stage, usually not treatable by surgery, and resistant to drugs that work in many other cancers.[ii] A potential new option for targeted treatment is on the horizon.

Injection directly into tumor ball

RenovoRx has developed RenovoCath, a dual-balloon infusion catheter, for targeted chemotherapy delivery.

[i] Lola Rahib et al. “Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States.” Cancer Research. Published Online First May 19, 2014.

[ii] Jim Stallard. Why is Pancreatic Cancer so Hard to Treat, Memorial Sloane Kettering Cancer Center, accessed March 20, 2019.

Clinical Trial Now Enrolling

A new option for patients with pancreatic cancer

RenovoRx’s TIGeR-PaC pivotal study is currently enrolling newly-diagnosed locally advanced pancreatic cancer patients. This is a randomized study of Trans-Arterial Micro-Perfusion (TAMP™) vs. systemic chemotherapy.

In The News

RenovoRx Announces Sixth U.S. Patent

TIGeR-PaC — a Phase III Clinical Trial Continues Enrolling Pancreatic Cancer Patients in the U.S. and Europe Los Altos, CA, June 9, 2020 – RenovoRx, an innovator in targeted cancer…
Read More

* Individual results may vary.